Industry

ROSEVILLE, Calif.–(BUSINESS WIRE)–HomeCEU, a leader in continuing education (CE) for healthcare professionals with a focus in therapy professions, today announced the introduction of its New OT Grad Toolkit. This employment toolkit is designed to walk a new occupational therapy (OT) graduate through the process of landing their first job in healthcare. “Entering the workforce in … [Read more…]

Applications are supported by the Phase 3 KEYNOTE-B15 results, which showed that KEYTRUDA plus Padcev demonstrated a statistically significant and clinically meaningful improvement in event-free survival and overall survival in study participants If approved, these regimens would be the first and only perioperative treatments for patients with MIBC regardless of cisplatin eligibility, marking potential new … [Read more…]

MUMBAI, India & BASEL, Switzerland–(BUSINESS WIRE)–#Amporin–SynSmart Rasayan Research Private Limited and Amporin Pharmaceuticals AG today announced a collaboration to develop breakthrough small molecule therapeutics for the treatment of deadly degenerative diseases. Under the terms of this collaboration, SynSmart will synthesize a substantial library of novel membrane-protecting molecules at its Mumbai research facility. Upon screening, the … [Read more…]

IRVINE, Calif.–(BUSINESS WIRE)–#Healthcare—SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering … [Read more…]

SYNTHBODY™ introduces a new class of “smart drugs”: protein therapeutics with built-in, multi-layered logic gates that actively change how they behave based on what they encounter in the body, a capability previously unseen in any approved protein drug Technology enables targeting of combinatorial “Synthetic Targets,” achieving >30x greater internalization, >80x greater in vitro potency and … [Read more…]

The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure DEERFIELD, Ill.–(BUSINESS WIRE)–Lundbeck today presented new real-world 6-month results from the INFUSE study at the American Academy of Neurology (AAN) 2026 Annual Meeting, underscoring the importance … [Read more…]

NEW YORK–(BUSINESS WIRE)–Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious … [Read more…]

PHOENIX–(BUSINESS WIRE)–At this year’s American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies focused on glucagon-like peptide-1 (GLP-1) agonist usage in patients undergoing surgery. GLP-1 agonists are a class of medications commonly prescribed to treat type 2 diabetes and obesity, and their therapeutic … [Read more…]

PHOENIX–(BUSINESS WIRE)–At this year’s American Society of Regional Anesthesia and Acute Pain Medicine (ASRA) annual meeting, investigators at Hospital for Special Surgery (HSS) presented significant studies leveraging artificial intelligence (AI) to provide insights into long-term pain risk after surgery and what patients want to know about anesthesia. These insights may ultimately help guide anesthesiologists’ consultations … [Read more…]

-Efficacy and safety data shared at IMMUNOLOGY2026 reinforce potential of ZL-1503 as a first-in-class treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Strong inhibition of both inflammatory and pruritic pathways over 112 days following a single dose of ZL-1503, together with a favorable preclinical safety profile, supports potential for less frequent dosing … [Read more…]